Supernus Announces Third Quarter 2026 Financial Results
Globe Newswire•29/10/2026•16:05 ET
0
Key Highlights
- ➤Third-quarter revenue $226.8M, up 18% year over year
- ➤Four growth products generated $192.2M, up 29% year over year
- ➤2026 revenue guidance raised to $875M-$900M from $860M-$890M
- ➤Indivior merger expected November 2, with $125M annual synergies
- ➤ONAPGO received seven-year orphan-drug exclusivity and posted $17.1M sales
Expert Statements
Jack Khattar, President and Chief Executive Officer of Supernus
“Our strong operating execution year-to-date delivered total revenue growth of 29%, which shows the continued momentum across our commercial portfolio, specifically our growth products.”
Jack Khattar, President and Chief Executive Officer of Supernus
“We look forward to closing the merger with Indivior next week, which will create a diverse CNS biopharmaceutical leader positioned to serve more patients and deliver long-term value for shareholders.”
* Record total revenues of $226.8 million in the third quarter 2026, an 18% increase compared to same period last year.
* Combined revenues of the Company's four growth products increased to $192.2 million in the third quarter 2026, representing an increase of 29% compared to the same period last year. This strong growth was driven by an increase in net sales of Qelbree(® ), GOCOVRI(®), ZURZUVAE(®), and ONAPGO™.
Get started
Create a free account to read the full story.